Abstract:BACKGROUND:Anti-angiogenic biologicals represent an important concept for the treatment of vasoproliferative diseases. However, the need for continued treatment, the presence of nonresponders, and the risk of long-term side effects limit the success of existing therapeutic agents. Although Tspan12 has been shown to regulate retinal vascular development, nothing is known about its involvement in neovascular disease and its potential as a novel therapeutic target for the treatment of vasoproliferative diseases.METHODS:Rodent models of retinal neovascular disease, including the mouse model of oxygen-induced retinopathy and the very low density lipoprotein receptor knockout mouse model were analyzed for Tspan/β-catenin regulation. Screening of a phage display of a human combinatorial antibody (Ab) library was used for the development of a high-affinity Ab against Tspan12. Therapeutic effects of the newly developed Ab on vascular endothelial cells were tested in vitro and in vivo in the oxygen-induced retinopathy and very low density lipoprotein receptor knockout mouse model.RESULTS:The newly developed anti-Tspan12 Ab exhibited potent inhibitory effects on endothelial cell migration and tube formation. Mechanistic studies confirmed that the Ab inhibited the interaction between Tspan12 and Frizzled-4 and effectively modulates β-catenin levels and target genes in vascular endothelial cells. Tspan12/β-catenin signaling was activated in response to acute and chronic stress in the oxygen-induced retinopathy and very low density lipoprotein receptor mouse model of proliferative retinopathy. Intravitreal application of the Ab showed significant therapeutic effects in both models without inducing negative side effects on retina function. Moreover, combined intravitreal injection of the Ab with a known vascular endothelial growth factor inhibitor, Aflibercept, resulted in significant enhancement of the therapeutic efficacy of each monotherapy. Combination therapy with the Tspan12 blocking antibody can be used to reduce anti-vascular endothelial growth factor doses, thus decreasing the risk of long-term off-target effects.CONCLUSIONS:Tspan12/β-catenin signaling is critical for the progression of vasoproliferative disease. The newly developed anti-Tspan12 antibody has therapeutic effects in vasoproliferative retinopathy and can enhance the potency of existing anti- vascular endothelial growth factor agents.

Anti-angiogenic Effect of a Humanized Antibody Blocking the Wnt/β-catenin Signaling Pathway.

A Monotargeting Peptidic Network Antibody Inhibits More Receptors for Anti-Angiogenesis

A peptidic network antibody inhibits both angiogenesis and inflammatory response

Antibody-Mediated Inhibition of Tspan12 Ameliorates Vasoproliferative Retinopathy Through Suppression of Β-Catenin Signaling.

Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

Vascular Endothelial Growth Factor Receptor 2 Antibody, BC001, Attenuates Laser-Induced Choroidal Neovascularization in Rhesus Monkeys (Macaca mulatta)

Anti-angiogenesis and anti-tumor activity of the fully human anti-VEGF165 monoclonal antibody obtained from the five-feature transgenic mice

Inhibited Experimental Corneal Neovascularization By Neutralizing Anti-Sdf-1 Alpha Antibody

An antibody-like peptidic network for anti-angiogenesis

Joint Antiangiogenic Effect of Atn-161 and Anti-Vegf Antibody in A Rat Model of Early Wet Age-Related Macular Degeneration

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

A Humanized Anti-Dll4 Antibody Promotes Dysfunctional Angiogenesis and Inhibits Breast Tumor Growth.

Nanoparticle-mediated Expression of a Wnt Pathway Inhibitor Ameliorates Ocular Neovascularization.

A Murine–human Chimeric IgG Antibody Against Vascular Endothelial Growth Factor Receptor 2 Inhibits Angiogenesis in Vitro

An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization

Inhibition Of Pathologic Corneal Neovascularization By Topical Application Of A Novel Peptide In Vivo

Anti-apoptosis Effects of Vascular Endothelial Cadherin in Experimental Corneal Neovascularization.

Evaluation of the binding and anti-angiogenic capacity of anti-vascular endothelial growth factor receptor 2 nanobody (anti-vegfr2 nanobody)

Bispecific gene antibody(Anti-human Bladder Carcinoma/Anti-VEGF) on animal model of bladder carcinoma

Inhibition Of Pathological Corneal Neovascularization By A Small Peptide Derived From Human Apolipoprotein (A) Kringle V

Screening and construction of nanobodies against human CD93 using phage libraries and study of their antiangiogenic effects